current immunotherapeutic approaches in dlbcl: the value of car-t cells and bispecific antibodies
Published 1 year ago • 241 plays • Length 2:52Download video MP4
Download video MP3
Similar videos
-
2:38
weighing up the pros and cons of car-t therapy and bispecific antibodies in r/r dlbcl
-
1:04
bispecifics & car-t therapy in dlbcl: sequencing and selecting between these agents
-
1:30
bispecific antibodies for r/r aggressive b-cell lymphomas
-
1:40
current & future outlooks on car-t therapy & bispecific antibodies in follicular lymphoma
-
1:48
novel immunotherapy approaches in lymphoma: car-t cells, bispecifics & sequencing
-
6:23
the benefits of bispecific antibodies over car-t cell therapy in lymphoma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
38:40
bispecific antibodies in lymphoma: an update
-
19:39
t-cell engagers: targets, challenges and opportunity
-
10:30
blood cancers explained: leukemia, myeloma, lymphoma, and more
-
2:34
car-t & bispecific antibodies in second-line dlbcl
-
2:29
emerging lymphoma therapies: bispecific antibodies and car t-cells
-
12:15
car-t vs bispecific antibodies for lymphoma
-
1:14
the car t-cell strategy vs bispecific antibodies
-
2:37
efficacy of bispecific cd19/cd22 car t-cells in b-cell malignancies
-
3:43
safety and efficacy of ytb323, a car t-cell therapy, in r/r dlbcl
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
0:45
bispecific car t-cell therapy: combining anti-cd19 and cd22 car t-cells
-
1:50
outcomes of patients with dlbcl following asct and/or car-t
-
1:55
treatment options for dlbcl patients who relapse after car-t cell therapy
-
2:14
comparing car t-cell toxicity in all and lymphoma
-
2:27
the potential of car t-cell therapy in combination with antibodies for the treatment of all